New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company received three notices of allowance in countries within the European Patent Organization (EPO), including Germany, UK, France, Italy, Spain, and over 30 additional nations within the European Patent Treaty IRVINE, Calif., Nov. 21,... Read More

IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biomerica until May 5, 2025, to... Read More

Patients experiencing bloating and gastrointestinal discomfort can now order inFoods ® IBS directly from www.infoodsIBS.com without needing to visit a doctor’s office With a simple, at-home finger-prick blood sample, patients can receive a personalized test result identifying potential IBS trigger foods The inFoods ® IBS test empowers patients with actionable results to reduce bloating and gastrointestinal pain IRVINE,... Read More

Total Revenue Increases 6% Over Same Period Last Year Cost-Saving Measures Now Implemented, Expected to Reduce Annual Expenses by 16% to 23%, Representing $1.0 to $1.4 Million Reduction Biomerica's At-Home PSA Screening Test Receives Saudi Food and Drug Authority (SFDA) Approval for Early Detection of Prostate Cancer IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global... Read More

10-Minute At-Home PSA Test for Early Detection of Prostate Cancer First order already shipped to Saudi Arabia Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel ® Prostate (PSA) Screening Test to be sold and used in the country.... Read More

Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger Growth Significant Cost Savings Plan Implemented After Year End – Expected to Deliver Expense Reductions of $1.0 to $1.4 Million in the Coming Year inFoods ® IBS Pilot with Large 1,100 Physician Group Progressing Ahead of Schedule IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today... Read More

inFoods ® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick methodology in the privacy of their home inFoods ® IBS test is the first of its kind to identify specific foods that can trigger an Irritable Bowel Syndrome (IBS) symptoms IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, is proud to announce a... Read More

With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis by all physicians, IBS represents a significant healthcare burden. inFoods IBS offers a groundbreaking method to identify foods that can trigger IBS symptoms, revolutionizing how IBS symptoms are managed.... Read More

Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect ™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer worldwide Aware® is an FDA cleared simple at-home device clinically tested to increase sensitivity in breast self-exams; about 80% of breast cancers are detected by women... Read More

Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. Average quarterly increase in p hysicians prescribing i nFoods more than doubled each quarter over the past 12 months. Biomerica in discussions for launch of inFoods IBS with large non-GI physician groups opening new market for the product. Company receives notice of allowance for five new patents in... Read More

Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference in the DDW Irritable Bowel Syndrome (IBS) Clinical Session Company in discussions with Key Clinical Lab Customers for Use of its Recently US FDA 510(k) Cleared Hp... Read More

Collaborators at the University of Michigan will present new Data on InFoods ® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods... Read More

IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, “LabCorp” (NYSE: LH), brings extensive expertise to collaborate with Jack Kenny, Chairman... Read More

Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology... Read More

Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of 2023. Loss per shares narrows to $0.09 per share from $0.12 per share reflecting disciplined operating expense management. Company Received US FDA 510(k) Clearance for Its Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects approximately 35% of the U.S.... Read More

Over 80% of gastric cancers are attributed to H. pylori bacterial infection Gastric cancer is the third most common cause of cancer related death in the world H. pylori infection is also a major cause of peptic ulcers IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic products, today announced it has received U.S. Food and Drug... Read More

IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which... Read More

Biomerica remains on track for inFoods ® IBS national rollout during calendar 2024, and expects strong product revenue growth during national rollout Veteran Vice President of Sales and National Accounts hired along with first set of regional sales representatives IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced... Read More

Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024 vs the first fiscal quarter of 2023 Company believes current cash position, forecasted revenue growth and corporate strategy is expected to enable it to achieve profitability GAAP gross margin percentage of 24.1% for the first fiscal quarter of 2024 improved substantially over -3.4% for the first fiscal quarter of 2023 Company completes... Read More

Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024 vs the first fiscal quarter of 2023 Company believes current cash position, forecasted revenue growth and corporate strategy is expected to enable it to achieve profitability GAAP gross margin percentage of 24.1% for the first fiscal quarter of 2024 improved substantially over -3.4% for the first fiscal quarter of 2023 Company completes... Read More

IRVINE, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that the Dubai government has officially approved insurance reimbursement for the EZ Detect colorectal disease at-home screening test, which is designed to detect an early warning sign of colorectal cancer and other colorectal diseases. Colorectal cancer (“CRC”) is the second most common cause of cancer death in... Read More

NEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Maxim Group LLC, a full-service investment banking, securities and wealth management firm, and M-Vest, a digital community built for issuers, investors, and thought leaders, present the Virtual Tech Conference Series: Emerging Growth in A.I. The conference will take place on Tuesday, September 26 th , & Wednesday, September 27 th , 2023, starting at 8:00 a.m. ET. We will be... Read More

Kenny has proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian Bioscience As CEO Kenny managed the sale of Meridian Biosciences in an all-cash transaction valued at approximately $1.53 billion NEWPORT BEACH, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global... Read More

Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods ® IBS pilot program with one of the largest Gastrointestinal physician groups in the US inFoods IBS completes pre-launch phase; Veteran VP of sales and national accounts hired; On track for national launch by calendar Q1 2024 IRVINE, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the... Read More

Over 7,000 CVS Pharmacy Stores to sell the EZ Detect ™ Test Simple 2 minute at-home test detects an early warning sign of colorectal cancer IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that CVS Pharmacy has begun in-store sales rollout of the Company’s EZ Detect™ colorectal disease screening test in over 7,000 stores nationwide throughout the CVS Pharmacy... Read More

Patent Claims Describe a Novel System to Predict and Help Prevent Adverse Food Reactions Using Personal Medical Data The Patent further describes Algorithms to help Determine Safety Levels of Food Ingredients, Offering a Personalized Approach to Dietary Interventions and Safety IRVINE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative diagnostic... Read More

Gastro Health, a leading gastroenterology group, plans to utilize this simplified blood collection method when recommending the inFoods ® IBS to their patients Biomerica also announced that inFoods ® IBS clinical trial data was presented at the DDW conference May 8 th .The data showed that the inFoods ® IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API) inFoods IBS... Read More

Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United States Clinical study results show patients who eliminated foods as determined by the inFoods® IBS test experience significant improvement in IBS Symptoms Including Abdominal Pain Intensity (API) IRVINE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical... Read More

For the nine months ended February 28, 2023 vs. the same period in 2022, revenues, excluding sales of Covid-related products, increased by 16%. InFoods ® IBS Laboratory Developed Test (LDT) validation testing at the CLIA Lab has been completed, patient testing now underway. IRVINE, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc . (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic... Read More

InFoods ® IBS LDT validation testing at the CLIA Lab is completed and the product is now being offered commercially Clinical trial data shows InFoods ® IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API) The improvement in API for patients in the treatment arm versus the placebo arm was similar to, and in some cases better than, the current IBS drugs in the market.... Read More

IRVINE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share for total gross proceeds of $8 million, before deducting underwriting... Read More

IRVINE, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the pricing of its previously announced underwritten public offering. Biomerica is offering an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share. All shares of common stock in the offering are... Read More

IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today that it has commenced an underwritten public offering of its common stock. All shares of common stock in the proposed offering are being offered by Biomerica. The offering is subject to market conditions, and there can be no assurance as to whether or when the... Read More

InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs Launch of InFoods ® IBS Lab Developed Test Expected in Fiscal 3Q Amazon Now Fulfills Sales of... Read More

Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the former Editor in Chief of Clinical and Translational Gastroenterology, and has served as the co-Chairman for the Rome IV Committee on Functional Bowel Disorders . Dr. Lacy has authored over 225 peer reviewed articles IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent... Read More

Expands Commercialization Efforts in Areas with High Unmet Needs IRVINE, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) received clearance from the Kingdom of Saudi Arabia Food and Drug Administration (KFDA), and the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) for the EZ Detect™ Colon Disease test and the Aware® Breast Self Exam device. The Company is working... Read More